Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,800 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

NCT02239354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
VC-01™ Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 2, 2026, 11:20 PM EDT
Completed No phase listed Observational

Differences in Genes and Proteins in Active and Controlled Uveitis

NCT00357266
View directory record Official record
Conditions
Ocular Inflammatory Disease, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 11:20 PM EDT
Terminated Phase 1Phase 2 Interventional

Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

NCT03116529
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Combination Radiation, Immunotherapy, Surgery
Combination Product
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 2, 2026, 11:20 PM EDT
Enrolling by invitation Not applicable Interventional

The ELG Analysis of Glucose a Correlational to Blood Glucose Assay

NCT05055804
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
ELG
Device
Lead sponsor
XP Technology, LLC
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Springdale, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01807377
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-05175157, Midazolam, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PE0139 Injection, Placebo
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Anniston, Alabama • Hialeah, Florida • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 1 Interventional

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

NCT01708044
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide acetate, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 2, 2026, 11:20 PM EDT
Recruiting No phase listed Observational

Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

NCT02000687
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

NCT04398030
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes
Interventions
coil-reinforced soft polymer indwelling cannula, soft Teflon indwelling catheter
Device
Lead sponsor
Capillary Biomedical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 2, 2026, 11:20 PM EDT
Terminated Phase 4 Interventional

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
h-Patch
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 2, 2026, 11:20 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Autonomic and Vascular Function

NCT06786546
View directory record Official record
Conditions
Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Diabetes, Autoimmune
Interventions
Not listed
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 2, 2026, 11:20 PM EDT
Completed No phase listed Observational

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

NCT00948311
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorder
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
12 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) in a Closed-Loop System

NCT05610111
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CLC + BAM, CLC + ABC
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Omnipod 5 System Compared to Pump Therapy

NCT05409131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Omnipod 5 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

NCT04784637
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional Results available

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

NCT00974051
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Terbutaline, 20% basal insulin reduction, Control
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 2, 2026, 11:20 PM EDT
Terminated Phase 4 Interventional

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

NCT00961207
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Oct 2, 2026, 11:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 2, 2026, 11:20 PM EDT
Completed Not applicable Interventional

Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms in Adolescents With Type 1 Diabetes Mellitus

NCT03655067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Depressive Symptoms
Interventions
CATCH-IT
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 2, 2026, 11:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

NCT06931275
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
EMR-based BPA model, Placebo (EMR-based without BPA model)
Other · Behavioral
Lead sponsor
T1D Exchange, United States
Other
Eligibility
2 Years to 95 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 2, 2026, 11:20 PM EDT